Abbott Laboratories closed 6.08% below its 52-week high of $141.23, which the company reached on March 4th.

In a report released yesterday, Larry Biegelsen from Wells Fargo maintained a Buy rating on Abbott Laboratories (ABT – Research Report), with a ...

In a report released on March 27, Josh Jennings from TD Cowen reiterated a Buy rating on Abbott Laboratories (ABT – Research Report), with a ...

In this article, we are going to take a look at where Abbott Laboratories (NYSE:ABT) stands against other stocks that jumped, defying market uncertainties on Thursday. The stock market extended ...

Unfortunately for shareholders, while the Abbott Laboratories (NYSE:ABT) share price is up 65% in the last five years, that's less than the market return. Looking at the last year alone ...

This month, we explore the 125-year-old history of Abbott Laboratories and its most significant milestone to date – the creation of its own independent company, AbbVie. In 1888, a 30-year-old ...

The ABBOTT PRISM System is an automated immunoassay ... technology is now being used in most major hospitals and reference laboratories and is now available in the transfusion market.

Abbott Laboratories has maintained a strong position in the healthcare industry, with a diverse portfolio spanning medical devices, diagnostics, nutrition, and branded generic pharmaceuticals.

Abbott (shoulder) allowed two runs over 5.2 innings in his first rehab start with Triple-A Louisville on Tuesday.